Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

↑, increase; ↓, decrease; ω-3, omega 3; aLM, appendicular lean mass; BCAA, branched-chain amino acids; BMI, body mass index; CaHMB, calcium β-hydroxy-β-methylbutyrate; CRP, c reactive protein; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; FOXO1, forkhead box protein O1; LC3b, microtubule-associated protein 1A/1B-light chain 3; LEBDs, leucine enriched BCAA dietary supplement; MHS, muscular handgrip strength; MQ, muscle quality; NEHMB, ad libitum diet plus CaHMB; NEPLA, ad libitum diet plus placebo; REHMB, ad libitum diet plus CaHMB and resistance exercise; REPLA, ad libitum diet plus placebo and resistance exercise; RTI, resistance training intervention; SBDs, standard BCAA dietary supplement; VD, vitamin D; y, years.

Source: 3. Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Systematic review.

Systematic review

Uses explicit methods to identify, assess and summarise research on a defined question.

Meta-analysis unclear · Blinding not applicable to this review · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Insights into Pathogenesis, Nutritional and Drug Approach in Sarcopenia: A Systematic Review

Source: Article title.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Insights into Pathogenesis, Nutritional and Drug Approach in Sarcopenia: A Systematic Review

Systematic review · Biomedicines · 2023

Original publication title

Insights into Pathogenesis, Nutritional and Drug Approach in Sarcopenia: A Systematic Review

Rodrigo Haber Mellen; Otávio Simões Girotto; Eduarda Boni Marques; Lucas Fornari Laurindo; Paulo Cesar Grippa; Claudemir Gregório Mendes; Lorena Natalino Haber Garcia; Marcelo Dib Bechara; Sandra Maria Barbalho; Renata Vargas Sinatora; Jesselina Francisco dos Santos Haber; Uri Adrian P. Flato; Patricia Cincotto dos Santos Bueno; Claudia Rucco Penteado Detregiachi; Karina Quesada

© 2023 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Sarcopenia is a multifactorial condition related to the loss of muscle mass and strength due to aging, eating habits, physical inactivity, or even caused by another disease. Affected individuals have a higher risk of falls and may be associated with heart disease, respiratory diseases, cognitive impairment, and consequently an increased risk of hospitalization, in addition to causing an economic impact due to the high cost of care during the stay in hospitals. The standardization of appropriate treatment for patients with sarcopenia that could help reduce pathology-related morbidity is necessary.

For these reasons, this study aimed to perform a systematic review of the role of nutrition and drugs that could ameliorate the health and quality of life of sarcopenic patients and PRISMA guidelines were followed. Lifestyle interventions have shown a profound impact on sarcopenia treatment but using supplements and different drugs can also impact skeletal muscle maintenance. Creatine, leucine, branched-chain amino acids, omega 3, and vitamin D can show benefits. Although with controversial results, medications such as Metformin, GLP-1, losartan, statin, growth hormone, and dipeptidyl peptidase 4 inhibitors have also been considered and can alter the sarcopenic’s metabolic parameters, protect against cardiovascular diseases and outcomes, while protecting muscles.

Authors’ abstract

Sarcopenia is a multifactorial condition related to the loss of muscle mass and strength due to aging, eating habits, physical inactivity, or even caused by another disease. Affected individuals have a higher risk of falls and may be associated with heart disease, respiratory diseases, cognitive impairment, and consequently an increased risk of hospitalization, in addition to causing an economic impact due to the high cost of care during the stay in hospitals. The standardization of appropriate treatment for patients with sarcopenia that could help reduce pathology-related morbidity is necessary.

For these reasons, this study aimed to perform a systematic review of the role of nutrition and drugs that could ameliorate the health and quality of life of sarcopenic patients and PRISMA guidelines were followed. Lifestyle interventions have shown a profound impact on sarcopenia treatment but using supplements and different drugs can also impact skeletal muscle maintenance. Creatine, leucine, branched-chain amino acids, omega 3, and vitamin D can show benefits. Although with controversial results, medications such as Metformin, GLP-1, losartan, statin, growth hormone, and dipeptidyl peptidase 4 inhibitors have also been considered and can alter the sarcopenic’s metabolic parameters, protect against cardiovascular diseases and outcomes, while protecting muscles.

Publication and source details

Original title: Insights into Pathogenesis, Nutritional and Drug Approach in Sarcopenia: A Systematic Review

Rodrigo Haber Mellen; Otávio Simões Girotto; Eduarda Boni Marques; Lucas Fornari Laurindo; Paulo Cesar Grippa; Claudemir Gregório Mendes; Lorena Natalino Haber Garcia; Marcelo Dib Bechara; Sandra Maria Barbalho; Renata Vargas Sinatora; Jesselina Francisco dos Santos Haber; Uri Adrian P. Flato; Patricia Cincotto dos Santos Bueno; Claudia Rucco Penteado Detregiachi; Karina Quesada

Biomedicines · 2023

* Correspondence: smbarbalho@gmail.com; Tel.: 55-14-99655-3190© 2023 by the authors.2023https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).This research received no external funding.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T08:10:07.604392+00:00

DOI: 10.3390/biomedicines11010136 · PMC9856128